Symbol="CKPT"
AssetType="Common Stock"
Name="Checkpoint Therapeutics Inc"
Description="Checkpoint Therapeutics, Inc., a clinical-stage immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is headquartered in New York, New York."
CIK="1651407"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="62509000"
EBITDA="None"
PERatio="None"
PEGRatio="0"
BookValue="-1.595"
DividendPerShare="0"
DividendYield="0"
EPS="-6"
RevenuePerShareTTM="0.013"
ProfitMargin="0"
OperatingMarginTTM="-340.31"
ReturnOnAssetsTTM="-1.525"
ReturnOnEquityTTM="-12.2"
RevenueTTM="175000"
GrossProfitTTM="-48185000"
DilutedEPSTTM="-6"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.327"
AnalystTargetPrice="29.8"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="277.67"
PriceToBookRatio="8.56"
EVToRevenue="105.41"
EVToEBITDA="-0.198"
Beta="1.439"
num_52WeekHigh="14.9"
num_52WeekLow="1.84"
num_50DayMovingAverage="2.752"
num_200DayMovingAverage="4.817"
SharesOutstanding="16593600"
DividendDate="None"
ExDividendDate="None"
symbol="CKPT"
open="3.36"
high="3.49"
low="3.31"
price="3.41"
volume="178113.00"
latest_trading_day="2023-07-21"
previous_close="3.30"
change="0.11"
change_percent="3.3333%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="80"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="20"
Volume_recent_avg="266243"
Change_recent_avg="-0.03"
Delta_recent_avg="0.31"
Variance_recent_avg="0.15"
Change_ratio_recent_avg="-1.0"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="20"
Aroon_momentum_negative="80"
image_negative_thumbnail_id_1="1155"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0189.jpeg"
image_negative_thumbnail_id_2="510"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0095.jpeg"
image_neutral_thumbnail_id_1="563"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_neutral_thumbnail_id_2="597"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0002.jpeg"
image_positive_thumbnail_id_1="955"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0117.jpeg"
image_positive_thumbnail_id_2="685"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0023.jpeg"
image_professor_thumbnail_id_1="1176"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0010.jpeg"
image_professor_thumbnail_id_2="1182"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
